396 results on '"Gouttefangeas, Cécile"'
Search Results
2. Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer
3. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
4. Investigation of the antioxidant capacity of caramels: Combination of laboratory assays and C. elegans model
5. Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells
6. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
7. 1133 Characterization of CD4+ T cell responses against Rho C, a metastasis associated tumor antigen
8. 638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study
9. CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)
10. Adhering to adhesion: assessing integrin conformation to monitor T cells
11. The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer
12. Activated integrins identify functional antigen-specific CD8⁺ T cells within minutes after antigen stimulation
13. Generation of TCR-engineered reference cell samples to control T-cell assay performance
14. Actively personalized vaccination trial for newly diagnosed glioblastoma
15. Personalized cancer vaccines: adjuvants are important, too
16. Defining the Critical Hurdles in Cancer Immunotherapy
17. Chitin oligomers promote lymphoid innate and adaptive immune cell activation
18. Supplementary Data from PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
19. Data from PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
20. Supplementary Table 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
21. Supplementary Table 3 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
22. Supplementary Figure 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
23. Data from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
24. Supplementary Figure Legends from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
25. Supplementary Table 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
26. Supplementary Figure 2 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
27. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
28. Supplementary Methods and Materials from Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas
29. Data from Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
30. Supplementary Figure Legend from Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
31. Supplementary Figure 1 from Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
32. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
33. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
34. Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells
35. CAF-immune cell crosstalk and its impact in immunotherapy
36. Immunoguiding, the Final Frontier in the Immunotherapy of Cancer
37. CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)
38. 641 Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study
39. Simultaneous Identification of Functional Antigen-Specific CD8+ and CD4+ Cells after In Vitro Expansion Using Elongated Peptides
40. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
41. EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
42. Radiofrequency Ablation: The Percutaneous Approach
43. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
44. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
45. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
46. Chitin oligomers directly promote lymphoid innate and adaptive immune cell activation
47. Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells
48. Staining of activated ß2-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells.
49. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters
50. Integrin activation enables rapid detection of functional Vδ1+and Vδ2+γδ T cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.